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Abstract 
Galanin, a neuropeptide co-released from noradrenergic and serotonergic 
projection neurons to the dentate gyrus, has recently emerged as an 
important mediator for signaling neuronal activity to the subgranular 
neurogenic stem cell niche supporting adult hippocampal neurogenesis. 
Galanin and its receptors appear to play key roles in depression-like 
behaviour, and effects on hippocampal neurogenesis are relevant to 
pharmacological strategies for treating depression, which in part appear to 
rely on restoring altered neurogenesis. We previously demonstrated that the 
GalR2/3 receptor agonist Gal 2-11 is proliferative and proneurogenic for 
postnatal hippocampal progenitor cells; however, the specific receptor 
mediation remained to be identified.  
With the recent availability of M1145 (a specific GalR2 agonist), and SNAP 
37889 (GalR3 specific antagonist), we extend our previous studies and show 
that while M1145 has no proliferative effect, the co-treatment of postnatal rat 
hippocampal progenitors with Gal 2-11 and SNAP 37889 completely 
abolished the Gal 2-11 proliferative effects. Taken together, these results 
clearly demonstrate that GalR3 and not GalR2 is the specific receptor subtype 
that mediates the proliferative effects of galanin on hippocampal progenitor 
cells. These results implicate GALR3 in the mediation of galanin neurogenic 
effects and, potentially, its neurogenic anti-depressant effects.
Introduction 
Adult mammalian neurogenesis occurs within discrete regions of the CNS, 
including the subgranular zone of the hippocampal dentate gyrus (Lie, Song 
et al. 2004). Hippocampal neurogenesis is important for memory processing, 
learning and behavioral responses Gould, Beylin et al. (1999), (Shors, 
Miesegaes et al. 2001, Deng, Aimone et al. 2010). Reduced hippocampal 
neurogenesis is associated with mood and cognitive impairments observed 
under various pathological conditions, including epilepsy and Alzheimer’s 
disease (Malberg, Eisch et al. 2000, Jessberger, Zhao et al. 2007, 
Rockenstein, Mante et al. 2007, Barkas, Redhead et al. 2012). The 
mechanisms underlying neurogenic regulation remains poorly understood and 
the link between neural activity and the stem cell niche remains key to its 
understanding (Song, Zhong et al. 2012).  
GABA-ergic interneurons residing within the stem cell niche of subgranular 
cell layer of the dentate gyrus signal neuronal activity and co-release 
important neuropeptides under specific firing conditions (Hinson, Rowell et al. 
2015)(Zaben and Gray 2013). Elegant optogenetic experiments have shown 
that interneuron activation directly modulates subgranular stem cells where 
neuronal circuitry mechanisms regulate adult quiescent neural stem-cell fate 
decision (Song, Zhong et al. 2012). A number of co-released neuropeptides 
from these interneurons have been studied extensively in recent years, with 
vasoactive intestinal peptide and neuropeptide Y emerging as key modulators 
of neurogenesis (Howell, Doyle et al. 2005, Howell, Silva et al. 2007, Zaben, 
Sheward et al. 2009) (see (Zaben and Gray 2013) for a review). Galanin has 
particularly sparked interest for its potential role in regulating neurogenesis 
but also in learning and memory (Ogren, Kuteeva et al. 2006) and mood 
disorders (Kuteeva, Hokfelt et al. 2008, Saar, Lahe et al. 2013). This highly 
conserved 29 amino acid neuropeptide acts as an inhibitory hyperpolarizing 
neuromodulator via three G protein coupled receptors: GalR1, GalR2 and 
GalR3 (Mitsukawa, Lu et al. 2008). The activation of GalR1 and/or GalR3 
receptors results in a depression-like phenotype, while activation of the GalR2 
receptor attenuates depression-like behavior (Kuteeva, Hokfelt et al. 2008).  
We have previously shown that galanin 2-11 (AR-M1896), a GalR2/3 agonist, 
has a proliferative effect on hippocampal precursor cells. In this study, we 
specifically defined the receptor medication of this proliferative effect of 
galanin on postnatal hippocampal precursors using recently available 
pharmacological agents. We show that GalR3 receptor subtype mediates a 
proliferative effect on hippocampal progenitor cells and the endogenous cell 
proliferation of these cells in vitro. These findings together with our previous 
findings (Abbosh, Lawkowski et al. 2011) strongly implicate GalR3 as an 
important mediator of progenitor cell proliferation in the hippocampus, and 
importantly from a therapeutic perspective, implicate GalR3 as a target for 
drug discovery studies in the treatment of mood disorders and restoring 
learning and memory impairment. 
 
Materials and methods: 
Postnatal rat hippocampal cell culture  
Animal experimentation was conducted in compliance with the United 
Kingdom Animals (Scientific Procedures) Act, 1986. Every effort was made to 
minimize the number of animals used and their suffering. Rat hippocampal 
progenitor cell cultures were generated from postnatal Sprague Dawley rats 
(P7-10) as described previously (Howell, Scharfman et al. 2003). Briefly, 
hippocampi were dissected under sterile conditions and cut using a McIlwain 
tissue chopper. Tissue slices were digested with papain (2mg/mL, 22.0 U/mg, 
Sigma) in pre-warmed culture medium (Neurobasal A, Invitrogen; 2% B-27, 
Life Technologies; 0.5mM Glutamine, Sigma) for 30 mins at 37ºC. Following 
cell release by trituration, progenitor cells were purified on a two step Optiprep 
gradient by centrifugation for 15 mins at 400g. Viable cells were plated directly 
on pre-coated poly-L-lysine (50µg/mL, Sigma) 24 well plates at a density of 
100, 000 cells per mL in culture medium. Cells were washed and replaced 
with fresh culture medium 2 hours post plating. All culture medium contained 
1% antibiotic/antimycotic (Penicillin/Streptomycin and Fungizone, Life 
Technologies). Cells were grown under control conditions for 3DIV in a 
humidify incubator (5%CO2, 95% air, 37ºC). 
Pharmacology 
To examine the specific galanin receptor subtype mediating the proliferative 
effects on NSPCs (Abbosh, Lawkowski et al. 2011), we used three different 
peptides: Galanin 2-11 (AR-M1896) binds to GalR2 and GalR3 with similar 
affinity (Lu, Lundstrom et al. 2005).  SNAP 37889 is a selective GalR3 
antagonist (Swanson, Blackburn et al. 2005) whilst the novel peptide M1145 
[(RG)2-N-galnin(2-13)-VL-(P)3-(AL)2-A-amide] is a GalR2-specific agonist 
that has more than 90- and 76-fold higher affinity for GalR2 over GalR1 and 
GalR3, respectively (Runesson, Saar et al. 2009).  
Cells were then either maintained under control conditions or exposed to 
10nM of the GalR2 specific agonist M1145 (a concentration at which it does 
not interact with GALR3 (Runesson, Saar et al. 2009)). Cultures in separate 
wells were treated with the GalR2/3 agonist GAL 2-11 as a positive control, 
and to see whether we could replicate our previous findings (Abbosh, 
Lawkowski et al. 2011). To quantify proliferation, cells under different 
conditions were simultaneously pulsed with the S-phase marker BrdU for the 
terminal 6hrs prior to fixation. 
 
Assessment of cell proliferation: 
The thymidine analogue bromodeoxyuridine (BrdU) was used to measure cell 
proliferation. BrdU is incorporated into the DNA of proliferating cells during the 
S phase of the cell cycle (Kuhn and Cooper-Kuhn 2007). BrdU (Sigma) was 
added directly to cells in culture for the terminal 6 hours to a final 
concentration of 20µM. Experimental conditions were added at the same time. 
Cells were then fixed in 4% paraformaldehdye (PFA, Sigma) for 30 mins at 
4ºC.  
Immunohistochemistry: 
PFA fixed cells were washed with phosphate buffered saline (PBS) and then 
treated with 2M HCl for 30 mins at 37ºC for antigenic retrieval of BrdU. Non-
specific binding sites were blocked with 5% donkey blocking serum (DBS) in 
PBS with 0.1% Triton X (PBS-T) for 1 hour at 20ºC. Primary antibodies were 
diluted in 5% DBS in 0.1% PBS-T overnight at 4ºC. The following primary 
antibodies were used: rat anti-BrdU (1:200, AbD Serotec), mouse anti-rat 
nestin (1:200, BD Biosciences). Cells were washed with PBS. Secondary 
antibodies diluted in 0.1% PBS-T were then applied for 2 hours at 20ºC in 
darkness. Species specific Alexa Fluor 488 and 555 conjugates (Invitrogen) 
were used at a dilution of 1:1000. Cells were washed with PBS and 
counterstained with the nuclear stain 4',6-diamidino-2-phenylindole DAPI 
(5µg/mL, Sigma) diluted in ddH2O for 6 mins at 20ºC in darkness. Cells were 
then washed three times with PBS. To ensure specific fluorescence, negative 
controls were generated by omitting primary antibodies.  
 
Imagine, cell counting and statistical analysis: 
Images were taken on a DM RBE microscope (Leica Microsystems Limited) at 
20x magnification. Six systemically randomized fields per well were taken 
using the Leica Application Suite image-capturing system version 3.8.0. Data 
was averaged per well and expressed in cells/mm2 or as a percentage, based 
on a sample of 4 wells per condition per experiment. All experiments were 
repeated at least three times. Graph Pad prism data analysis software 
(GraphPad inc, San Diego, CA, USA) was used to plot data points. For 
statistical comparisons, Student’s t test or a one-way ANOVA was used with 
Neuman-Keuls post hoc tests (p < 0.05 considered significant). 
 
Results  
Consistent with our previous findings, GAL 2-11 as a GALR2/3 agonist 
enhanced the rate of hippocampal progenitor cell proliferation as measured by 
the increased mitotic index of nestin-expressing cells (0.21 ± 0.01 vs. 0.16 ± 
0.006) (Figure 1) (Abbosh, Lawkowski et al. 2011). However, the GalR2 
specific agonist M1145 had no effect on the rate of proliferation of this cell 
subpopulation (0.16 ± 0.007 vs. 0.16 ± 0.006) (Figure 1) suggesting a 
possibly pure GALR3 mediation. To examine this hypothesis, hippocampal 
cell cultures were again grown for 3DIV and treated with the GalR3-specific 
antagonist SNAP 37889 and pulsed with BrdU for the terminal 6 hours prior to 
fixation. Interestingly, SNAP 37889 (2.5uM) not only completely abolished the 
proliferative effect of Galanin 2-11 (0.09 ± 0.006 vs. 0.19 ± 0.004), but also 
significantly reduced the baseline rate of proliferation of hippocampal nestin 
expressing progenitor cells (0.10 ± 0.008 vs. 0.16 ± 0.006) (Figure 2). Taken 
together, these results clearly demonstrate that GalR3 mediates the 
proliferative effect of galanin on hippocampal progenitor cells and is 
implicated in endogenous cell proliferation of hippocampal progenitors cells in 
an in vitro culture system.  
 
  
 
 
Discussion 
Under physiological conditions, hippocampal neurogenesis is implicated in 
hippocampal-dependent learning and spatial memory (Kempermann 2002). 
Its reduction and altered quality in many diseases particularly chronic 
temporal lobe epilepsy (Hattiangady and Shetty 2010) may be potentially 
responsible for these patients learning and memory deficits (Barkas, Redhead 
et al. 2012) and depression-like behavior (Jessberger, Nakashima et al. 
2007). Neuropeptides including galanin have emerged as important 
modulators of hippocampal neurogenesis (Zaben and Gray 2013). In this 
regard, we have previously demonstrated a proliferative effect of the GalR2/3 
agonist galanin 2–11 on hippocampal progenitor cultures generated from 
postnatal Wistar rats (Abbosh, Lawkowski et al. 2011); suggesting an 
important role for this peptide in promoting hippocampal neurogenesis. We, 
herein, utilized the recent availability of the GalR2 specific agonist M1145 and 
the GalR3-specific antagonist SNAP 37889 to further delineate the receptor 
mediation of the proliferative effect of galanin on hippocampal progenitor cells 
in vitro. Our data demonstrated that while M1145 had no proliferative effects, 
SNAP37889 completely abolished the galanin 2-11 proliferative effect (Figure 
1). SNAP37889 has also reduced endogenous cell proliferation in cultures. 
These results, taken together with our previous finding in which GalR1 
involvement was excluded and transcripts for both GalR2 and GalR3 
receptors were identified in culture, identify GalR3 as the receptor mediator of 
galanin proliferative effects on postnatal hippocampal progenitor cells (Figure 
2). Since the mechanisms governing neurogenesis in the late postnatal period 
are highly conserved in adulthood (Pleasure, Collins et al. 2000), our findings 
may implicate GalR3 in the altered hippocampal neurogenesis in many 
adulthood diseases; particularly in depression where the behavioural effects 
of some antidepressants require hippocampal neurogenesis (Santarelli, Saxe 
et al. 2003). Indeed, galanin and its receptors play key roles in depression 
and its treatment (McLaughlin and Robinson 2002, Lu, Barr et al. 2005, Lu, 
Sharkey et al. 2007, Mitsukawa, Lu et al. 2008). While galanin receptor 
GalR1/2 agonists exhibit antidepressant-like effects in the rat forced swim test 
(Mitsukawa, Lu et al. 2008), GalR3 antagonists exhibit anxiolytic and 
antidepressant-like activity (Lu, Sharkey et al. 2007). Galanin is co-expressed 
in acetylcholinergic, serotonergic and noradrenergic projection neurons to the 
hippocampus, and can inhibit co-transmitter release (Fisone, Wu et al. 1987). 
It is, therefore, important to distinguish between direct actions on hippocampal 
precursor cells and indirect actions either on synaptic transmission of other 
neurotransmitters or actions on other neuronal systems in vivo. This may 
explain the paradoxical pro-neurogenic findings we report here and the 
antidepressant effects of GalR3 antagonists in-vivo, and clearly the 
elucidation of these interactions will require further study.  The value of this 
study is its demonstration of a direct role of galanin on hippocampal 
precursors mediated via the GalR3 receptor, which may serve as a target for 
development of novel antidepressant drugs through modulation of 
hippocampal neurogenesis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figures:  
 
Figure 1: GalR3 mediates the proliferative effects on hippocampal 
progenitor cells. Cultures were grown under control conditions for 3days in 
vitro and given a terminal 6 hour exposure to BrdU and experimental 
conditions (100nM Galanin 2-11 (Gal 2-11), 10nM M1145). Proportion of BrdU 
incorportating cells expressing nestin, with respect to the total number of BrdU 
incorporating cells. Data represents mean ± SE based on a sample that 
represents 12 wells per condition from 3 different experiments. Comparisons 
between control and treatment conditions are a one-way ANOVA with 
Neuman-Keul’s multiple comparison test (**, p < 0.01, ***, p < 0.001). 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 2: GalR3 antagonist SNAP decreases the proliferative effects on 
nestin expressing hippocampal progenitor cells. Cultures were grown 
under control conditions for 3days in vitro and given a terminal 6 hour 
exposure to BrdU and experimental conditions (100nM Galanin 2-11 (Gal 2-
11), 2.5uM SNAP 37889 (SNAP), combination of Galanin 2-11 and SNAP 
37889). Proportion of BrdU incorportating cells expressing nestin, with respect 
to the total number of BrdU incorporating cells. Data represents mean ± SE 
based on a sample that represents 12 wells per condition from 3 different 
experiments. Comparisons between control and treatment conditions are a 
one-way ANOVA with Neuman-Keul’s multiple comparison test (**, p < 0.01, 
***, p < 0.001). 
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